Clinical Trial Update: Fruquintinib Combined With Toripalimab and SOX Regimen in the First-line Treatment of Advanced Metastatic Gastric or Gastroesophageal Junction Adenocarcinoma [Phase 1, Phase 2]

View source ↗

Summary

A phase 1/2 trial evaluating Fruquintinib with Toripalimab and SOX chemotherapy as first-line treatment for advanced/metastatic gastric or gastroesophageal junc…

Upgrade for the full analysis, importance score, and drug timeline.

Diseases / indications

• Gastric Cancer
• Gastroesophageal Junction Adenocarcinoma

Drugs mentioned

• Fruquintinib (fruquintinib)
• SOX regimen (S-1 and oxaliplatin)
• Toripalimab (Toripalimab)

Snippet

Sponsor: The First Affiliated Hospital of Zhengzhou University | Conditions: Metastatic Gastric Cancer | Phase 1, Phase 2 | Status: UNKNOWN